Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E, Ulrich M, Epp A, Younan P, Sahetya D, Hensley K, Allred S, Huang LY, Hahn J, Gahnberg K, Treuting PM, Trueblood ES, Gosink JJ, Thurman R, Wo S, Spahr K, Haass EJ, Snead K, Miller D, Padilla M, Smith AJ, Frantz C, Schrum JP, Nazarenko N, Gardai SJ. Gray E, et al. Among authors: hensley k. J Immunother Cancer. 2023 Oct;11(10):e007572. doi: 10.1136/jitc-2023-007572. J Immunother Cancer. 2023. PMID: 37793853 Free PMC article.
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.
Mazahreh R, Mason ML, Gosink JJ, Olson DJ, Thurman R, Hale C, Westendorf L, Pires TA, Leiske CI, Carlson M, Nguyen LT, Cochran JH, Okeley NM, Yumul R, Jin S, Stone IJ, Sahetya D, Nesterova A, Allred S, Hensley KM, Hu R, Lawrence R, Lewis TS, Sandall S. Mazahreh R, et al. Among authors: hensley km. Mol Cancer Ther. 2023 Apr 3;22(4):421-434. doi: 10.1158/1535-7163.MCT-22-0401. Mol Cancer Ther. 2023. PMID: 36800443 Free PMC article. Clinical Trial.
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer.
Olson D, Taylor J, Willis K, Hensley K, Allred S, Zaval M, Farr L, Thurman R, Jain N, Hein R, Ulrich M, Peterson S, Kulukian A. Olson D, et al. Among authors: hensley k. Cancer Res Commun. 2023 Sep 25;3(9):1927-1939. doi: 10.1158/2767-9764.CRC-23-0302. Cancer Res Commun. 2023. PMID: 37721518 Free PMC article.
Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the Netherlands.
Jongkees MJ, Tan NH, Geers D, de Vries RD, Geurtsvankessel CH, Hensley KS, Sablerolles RSG, Bogers S, Gommers L, Blakaj B, Afonso PM, Hansen BE, Rijnders BJA, Brinkman K, van der Kuy PHM, Roukens AHE, Rokx C. Jongkees MJ, et al. Among authors: hensley ks. AIDS. 2024 May 24. doi: 10.1097/QAD.0000000000003933. Online ahead of print. AIDS. 2024. PMID: 38788210
See Thy Self.
Hensley K. Hensley K. S D Med. 2023 Oct;76(10):448. S D Med. 2023. PMID: 38232484 No abstract available.
A Case of Red Eye and Facial Swelling.
Victor-Linkenhoker V, Hensley K, Tavakoli T. Victor-Linkenhoker V, et al. Among authors: hensley k. Pediatr Rev. 2023 Oct 1;44(S1):S59-S62. doi: 10.1542/pir.2022-005737. Pediatr Rev. 2023. PMID: 37777235 No abstract available.
190 results